Table 1. Characteristics of laboratories that reported MRSA and livestock-associated MRSA ST398 isolates from human samples, Europe, 2007*.
Laboratory no. | Country | Type of laboratory | Source of MRSA isolates | No. MRSA isolates received | No. MRSA isolates typed | MRSA ST398 isolates |
|
---|---|---|---|---|---|---|---|
No. (%) | 95% CI | ||||||
1 | Austria | National ref | All | 523 | 523 | 0 | 0–0.7 |
2 | Austria | National ref | All | 586 | 586 | 16 (2.7) | 1.7–4.4 |
3 | Belgium | National ref | All | 329 | 149 | 7 (4.7) | 2.3–9.4 |
4 | Czech Republic | National ref | Blood | 37 | 10 | 0 | 0–27.8 |
5 | Denmark | National ref | All | 659 | 659 | 14 (2.1) | 1.3–3.5 |
Denmark | National ref | Clinical | 370 | 370 | 6 (1.6) | 0.7–3.5 | |
6 | Finland | National ref | All | 1,323 | 1,323 | 1 (0.1) | 0–0.4 |
7 | Germany | National ref | Clinical | 1,293 | 1,293 | 9 (0.7) | 0.4–1.3 |
8 | Germany | Regional ref | Clinical | 866 | 866 | 37 (4.3) | 3.1–5.8 |
9 | Greece | National ref | Clinical | 336 | 336 | 0 | 0–1.1 |
10 | Hungary | National ref | All | 365 | 63 | 0† | NA |
11 | Iceland | National ref | Clinical | 21 | 21 | 0 | 0–15.5 |
12 | Italy | National ref | Clinical | 108 | 108 | 1 (0.9) | 0.2–5.1 |
13 | Ireland | National ref | Clinical | 832 | 696 | 0 | 0–0.5 |
14 | The Netherlands | National ref | Clinical | 478 | 478 | 57 (11.9) | 9.3–15.1 |
15 | The Netherlands | Local | Clinical | 12 | 12 | 3 (25.0) | 8.9–53.2 |
16 | Sweden | National ref | All | 1,127 | 1,127 | 8 (0.7) | 0.4–1.4 |
17 | Switzerland | Local | Clinical | 587 | 65 | 0† | NA |
18 | Switzerland | Regional ref | All | 182 | 182 | 0 | 0–2.1 |
19 | Switzerland | Regional ref | Clinical | 64 | 64 | 0 | 0–5.7 |
20 | Switzerland | Local | All | 80 | 78 | 0 | 0–4.7 |
21 | Turkey | Local | Clinical | 198 | 60 | 0 | 0–6.0 |
*MRSA, methicillin-resistant Staphylococcus aureus; ST398, sequence type 398; CI, confidence interval; ref, reference laboratory; NA, not applicable. †Not reported because laboratory typed <25% of MRSA isolates.